Accepted for Publication: May 28, 2014.
Published Online: November 10, 2014. doi:10.1001/jamaneurol.2014.1817.
Study concept and design: Fleischmann, Ruprecht.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Fleischmann, Ruprecht.
Critical revision of the manuscript for important intellectual content: Fleischmann, Prüss, Rosche, Bahnemann, Gelderblom, Deuschle, Harms, Kopp.
Administrative, technical, or material support: Fleischmann, Rosche, Deuschle, Harms.
Study supervision: Harms, Kopp, Ruprecht.
Conflict of Interest Disclosures: Dr Rosche has participated in meetings sponsored by Bayer Healthcare, Merck Serono, Biogen Idec, Novartis, Ovamed, and Teva Pharmaceuticals and has received lecture fees and research support from these companies. Dr Harms has received speaking fees from Novartis, Biogen Idec, Merck-Serono, Diamed, and Bayer; honoraria for serving on advisory boards from Novartis, Biogen Idec, and Genzyme; and travel grants from Teva Pharmaceuticals, Merck Serono, and Biogen Idec. Dr Ruprecht has received research support from Novartis as well as speaking fees and travel grants from Bayer Healthcare, Biogen Idec, Merck Serono, sanofi-aventis/Genzyme, Teva Pharmaceuticals, and Novartis. No other disclosures were reported.
Funding/Support: Dr Ruprecht is supported by the German Ministry of Education and Research (BMBF/KKNMS, Competence Network Multiple Sclerosis).
Role of the Funder/Sponsor: The German Ministry of Education and Research had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.